San Diego-based mostly Viking Therapeutics marked by itself as a serious competitor in the weight loss drug industry in February after revealing promising facts from a mid-stage demo of experimental drug VK2735, which advised it rivaled—and outperformed—Novo and Lilly drugs when specified being a weekly injection and in March the company unveil